PROFILPELAJAR.COM

F-17464

F-17464
Clinical data
Other namesF17464; F-17,464
Routes of
administration		Oral[1]
Drug classDopamine D3 receptor antagonist; Serotonin 5-HT1A receptor agonist
ATC code
  • None
Pharmacokinetic data
Elimination half-life1.32 hours[2][3]
Identifiers
  • N-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]methanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H29N3O6S
Molar mass499.58 g·mol−1
3D model (JSmol)
  • CS(=O)(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCC3=COC4=CC5=C(C=C4C3=O)OCO5
  • InChI=1S/C25H29N3O6S/c1-35(30,31)26-19-6-4-7-20(13-19)28-11-9-27(10-12-28)8-3-2-5-18-16-32-22-15-24-23(33-17-34-24)14-21(22)25(18)29/h4,6-7,13-16,26H,2-3,5,8-12,17H2,1H3
  • Key:KLOYLPZTHLSRRB-UHFFFAOYSA-N

F-17464 is a dopamine D3 receptor antagonist and serotonin 5-HT1A receptor partial agonist which was under development for the treatment of schizophrenia but was never marketed.[1][4][2][5][6][3] It is taken orally.[1]

The drug's affinities (Ki) have been found to be 0.17 nM for the dopamine D3 receptor, 0.16 nM for the serotonin 5-HT1A receptor, and 8.9 to 12.1 nM for the dopamine D2 receptor, with more than 50-fold selectivity for the dopamine D3 receptor over the dopamine D2 receptor.[3][2][6] It also shows a much slower dissociation rate from the dopamine D3 receptor than from the dopamine D2 receptor.[6] The drug possesses low affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 437 nM and 1,995 nM, respectively).[2] F-17464 showed more than 80% occupancy of the dopamine D3 receptor and only 20% occupancy of the dopamine D2 receptor with positron emission tomography (PET) imaging in humans.[2][3][5][7] It inhibited amphetamine- and dizocilpine (MK-801)-induced hyperlocomotion in rodents.[5]

F-17464 was first described in the scientific literature by 2015.[8] It was under development by Pierre Fabre.[1][4] The drug reached phase 2 clinical trials for schizophrenia prior to the discontinuation of its development in 2021.[1][4] The findings of a phase 2 trial have been published.[3][2][9]

See also

References

  1. ^ a b c d e "F 17464". AdisInsight. 27 September 2021. Retrieved 9 June 2026.
  2. ^ a b c d e f Lobo MC, Whitehurst TS, Kaar SJ, Howes OD (January 2022). "New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics". Neuroscience and Biobehavioral Reviews. 132: 324–361. doi:10.1016/j.neubiorev.2021.11.032. PMC 7616977. PMID 34838528.
  3. ^ a b c d e Ahmad SR, Zeyaullah M, AlShahrani AM, Khan MS, Dawria A, Mohieldin A, et al. (2025). "Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia". BioImpacts. 15 30259. doi:10.34172/bi.30259. PMC 11954750. PMID 40161932.
  4. ^ a b c "Delving into the Latest Updates on F-17464 with Synapse". Synapse. 28 March 2026. Retrieved 9 June 2026.
  5. ^ a b c Sokoloff P, Le Foll B (January 2017). "The dopamine D3 receptor, a quarter century later". The European Journal of Neuroscience. 45 (1): 2–19. doi:10.1111/ejn.13390. PMID 27600596.
  6. ^ a b c Cosi C, Martel JC, Auclair AL, Collo G, Cavalleri L, Heusler P, et al. (January 2021). "Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist". European Journal of Pharmacology. 890 173635. doi:10.1016/j.ejphar.2020.173635. PMID 33065094.
  7. ^ Slifstein M, Abi-Dargham A, Girgis RR, Suckow RF, Cooper TB, Divgi CR, et al. (February 2020). "Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO". Psychopharmacology. 237 (2). Berl: 519–527. doi:10.1007/s00213-019-05387-w. PMID 31773210.
  8. ^ Joussot J (24 April 2015). Stratégies de synthèse d'un nouvel antipsychotique potentiel : cascades réactionnelles palladocatalysées : un outil puissant pour la synthèse de structures polycycliques complexes et hautement fonctionnalisées (phdthesis thesis) (in French). Université de Strasbourg. Retrieved 9 June 2026.
  9. ^ Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, et al. (October 2019). "Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia". Neuropsychopharmacology. 44 (11): 1917–1924. doi:10.1038/s41386-019-0355-2. PMC 6785149. PMID 30822774.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.